Journals By Industry - Antibiotic Resistance

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/454d3a/product_profiles) has announced the addition of the "Product Profiles: Marketed Antibacterials - Increasing genericization and fragmentation shape a crowded market" report to their offering. In the last two...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/0a092f/antibotics_and_ant) has announced the addition of John Wiley and Sons Ltd's new book "Antibotics and Antibotic Resistance" to their offering. This book, which is the translated version of a...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/df7978/antibiotic_resista) has announced the addition of the "Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance" report to their offering. This report gives a...

Astellas Pharma, Inc. and Theravance, Inc. have announced that Astellas Pharma has exercised its right to terminate the global license, development and commercialization agreement for VIBATIV(R) (telavancin) for injection, a bactericidal, once-daily lipoglycopeptide...

Biopharmaceutical Industry Veteran to Help Advance Strategic Value of Tetraphase's Promising Portfolio of Potent New Antibiotics WATERTOWN, Mass. -- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new...

Editor's Note: This is the first installment in a 12-part series on stocker cattle management. This series has been created in partnership with Chris McClare, Gold Standard Labs (bvd~pi.com), a lab services company,...

Introduction The probability of acquiring an infection in a healthcare setting is relatively high, and the risk of death is not negligible. Data from the Centers for Disease Control and Prevention (CDC) and...

Methicillin-resistant Staphylococcus aureus (MRSA) remains a leading cause of healthcare-associated infections (HAIs) (1) and is associated with higher morbidity and mortality rates, longer hospital stays, and greater costs than methicillin-susceptible S. aureus. (2)...

Company Monitor Indigenous Manufacturers Strengths One of two local pharmaceutical players. Substantial financial backing by the parent group. Offering contract manufacturing services. Leading local supplier of semi-synthetic penicillin. Regulatory approval in a number...

Multinational Companies Strengths One of the leading global pharmaceutical manufacturers. Strong presence in the vaccines sector. Diverse product portfolio. Weaknesses Difficult and unattractive marketplace, in view of the poor regulatory infrastructure. Counterfeit drugs...

SWOT Analysis Strengths Has a strong, well-established market position in Argentina. Substantial and diverse portfolio, with two operating divisions: pharmaceuticals and diagnostics. Roche has three patented products on the market in Argentina. Weaknesses...

Multinational Companies Strengths The leading multinational in Egypt. Well-established presence, including domestic facilities. Strong product portfolio, with four products among the 15 best-selling medicines. Good degree of vertical integration, operating manufacturing plants as...

MONMOUTH JUNCTION, N.J. -- TYRX([R]), Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections, today announcedthe appointment of Ron Salsbury as Vice President of Quality. Mr....

The Demonstration of Safety Advantages over Pfizer's Zyvox Will Be a Key Factor in Radezolid's Ability to Take Significant Market Share From Zyvox, According to Findings from Decision Resources BURLINGTON, Mass. -- Decision...

WOBURN, Mass. -- Excelimmune, Inc. today announced that the company has raised $12 million from a private investor. Proceeds will be used by Excelimmune to develop its infectious disease programs, including Staphguard, a...

Report Analyzes Dynamics of Product Usage, Physicians' Treatment Patterns and Patient Population EXTON, Pa. -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, will...

--Delafloxacin Achieves Statistical Superiority Over Vancomycin in Primary Endpoint, Investigators' Global Assessment of Cure-- --Results Strongly Support Planned Initiation of Phase 3 Study in 2H2012-- NEW HAVEN, Conn. -- Rib-X Pharmaceuticals, Inc., a...

The Overall Hospital-Treated MRSA Infections Drug Market Will Increase from $656 Million in 2010 to $730 Million in 2020, According to Findings from Decision Resources BURLINGTON, Mass. -- Second graph, third sentence should...

MRSA Infections are a Key Driver of Zyvox and Cubicin Usage, According to New Report from Arlington Medical Resources EXTON, Pa. -- Arlington Medical Resources (AMR), a provider of premier market intelligence for...